ReviewFrontiers in endocrinology2022
Advances in the treatment of secondary and tertiary hyperparathyroidism.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial.Naunyn-Schmiedeberg's archives of pharmacology · 2025Trial
- Incidence of Ectopic Parathyroid Glands in Primary, Secondary, and Tertiary Hyperparathyroidism.The Journal of surgical research · 2026Article
- Overcoming Stability Challenge During the Quantification of SHR6508 in Human Plasma by LC-MS/MS.Biomedical chromatography : BMC · 2026Article
- Serum Biomarker-Based Diagnostic Tools for Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis with Implications for Primary Care.Healthcare (Basel, Switzerland) · 2026Review
- [Brown tumor due to hyperparathyroidism secondary to chronic kidney disease: A clinical case].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Osteitis Fibrosa Cystica: An Unusual Cause of Left-Sided Chest Pain.Case reports in nephrology · 2026Article
- Diffuse skeletal [Asia Oceania journal of nuclear medicine & biology · 2026Article
- A case report of primary hyperparathyroidism due to a giant substernal parathyroid adenoma managed using a neck incision approach.Medicine · 2025Article
- Cinacalcet Efficacy in Hyperparathyroidism-Chronic Kidney Disease-Non-Dialysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation: Critical Review.Biomedicines · 2025Review
- Tertiary Hyperparathyroidism in Diabetic Nephropathy: An Underrecognized Complication-A Narrative Review.Biomedicines · 2025Review
- Parathyromatosis: The Pathogenic Background (Post-Parathyroidectomy Seeding or Exceptional Embryologic Remnant) and the Importance of a Fine Clinical Index for Recurrent Primary Hyperparathyroidism (a Narrative Review).Journal of clinical medicine · 2025Review
- Clinical value of serum iPTH, ALP and serum markers levels in patients with secondary hyperparathyroidism receiving paricalcitol combined with cinacalcet.Journal of medical biochemistry · 2025Article
- miRNAs in secondary hyperparathyroidism: literature review.BMC nephrology · 2025Review
- Lactobacillus johnsonii Generates Cyclo(pro-trp) and Promotes Intestinal CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Spectrum of parathyroid disorders in Pakistan: a review article.Annals of medicine and surgery (2012) · 2025Review
- Analysis of Clinical and Biochemical Parameters and the Effectiveness of Surgical Treatment in Patients with Primary Hyperparathyroidism: A Single-Center Study.Journal of clinical medicine · 2025Article
- Construction and validation of a predictive model for the serum phosphorus reduction after total parathyroidectomy in patients with secondary hyperparathyroidism.Frontiers in endocrinology · 2025Article
- Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.Current drug targets · 2025Review
- Safety evaluation of cinacalcet: Signal mining and analysis of adverse events based on the FAERS database.PloS one · 2025Article
- Precision stratified treatment of primary hyperparathyroidism based on multilevel emerging biomarkers.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary hyperparathyroidism (SHPT) and tertiary hyperparathyroidism (THPT) are common and complicated clinical endocrine diseases. The parathyroid glands maintain endocrine homeostasis by secreting parathyroid hormone to regulate blood calcium levels. However, structural alterations to multiple organs and systems occur throughout the body due to hyperactivity disorder in SHPT and THPT. This not only decreases the patients' quality of life, but also affects mortality. Since current treatments for these diseases remains unclear, we aimed to develop a comprehensive review of advances in the treatment of SHPT and THPT according to the latest relevant researches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.